Scholar Rock Holding, a preclinical biotech targeting growth factor inhibition for a variety of diseases, announced terms for its IPO on Monday.
The Cambridge, MA-based company plans to raise $75 million by offering 5.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Scholar Rock would command a fully diluted market value of $350 million.
Scholar Rock Holding was founded in 2012 and plans to list on the Nasdaq under the symbol SRRK. Jefferies, Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of May 21, 2018.
